Key Insights

Highlights

Success Rate

70% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 74/100

Termination Rate

30.0%

9 terminated out of 30 trials

Success Rate

70.0%

-16.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

43%

9 of 21 completed with results

Key Signals

9 with results70% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (2)
P 1 (17)
P 2 (11)

Trial Status

Completed21
Terminated9

Trial Success Rate

70.0%

Benchmark: 86.5%

Based on 21 completed trials

Clinical Trials (30)

Showing 20 of 20 trials
NCT00084682Phase 2Completed

Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01249443Phase 1Terminated

Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection

NCT01192815Phase 2Terminated

Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck

NCT01044433Phase 2Completed

Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck

NCT01064921Phase 1Completed

Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma

NCT00055913Phase 1Completed

Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT01316757Phase 2Completed

Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

NCT00895245Phase 2Terminated

Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy

NCT00095628Phase 2Completed

SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT01283178Phase 1Terminated

Phase I Study of IMRT and Molecular-Image Guided Adaptive Radiation Therapy for Advanced HNSCC

NCT00397384Phase 1Completed

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

NCT01254734Not ApplicableTerminated

Transoral Robotic Surgery in Treating Patients With Benign or Stage I-IV Head and Neck Cancer

NCT01682031Phase 2Terminated

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

NCT00387335Phase 2Completed

Sunitinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00101348Phase 1Completed

Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer

NCT00492089Phase 2Completed

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

NCT00098631Phase 2Completed

Lapatinib in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer

NCT00055770Phase 1Completed

Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer

NCT00049166Phase 1Completed

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

NCT00031681Phase 1Completed

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Scroll to load more

Research Network

Activity Timeline